Antares Pharma (ATRS) 10-Q 5 Nov 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Oct. 31, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	ATRS
Security Exchange Name	NASDAQ
Entity Registrant Name	ANTARES PHARMA, INC.
Entity Central Index Key	0001016169
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Title of 12(b) Security	Common Stock, par value $0.01 per share
Entity Common Stock, Shares Outstanding		163,226,089
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity File Number	1-32302
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1350192
Entity Address, Address Line One	100 Princeton South
Entity Address, Address Line Two	Suite 300
Entity Address, City or Town	Ewing
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08628
City Area Code	609
Local Phone Number	359-3020
Entity Interactive Data Current	Yes
Document Quarterly Report	true
Document Transition Report	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 41,874	$ 27,892
Accounts receivable	33,931	18,976
Inventories	16,503	11,350
Contract assets	6,199	10,442
Prepaid expenses and other current assets	1,429	2,648
Total current assets	99,936	71,308
Equipment, molds, furniture and fixtures, net	15,409	14,895
Operating lease right-of-use assets	5,462
Goodwill	1,095	1,095
Intangibles, net	508	831
Other assets	519	148
Total Assets	122,929	88,277
Current Liabilities:
Accounts payable	16,530	11,135
Accrued expenses and other liabilities	14,966	11,997
Long-term debt, current portion		3,043
Operating lease liabilities, current portion	975
Deferred revenue	1,412	1,018
Total current liabilities	33,883	27,193
Long-term debt	40,269	22,083
Operating lease liabilities, long-term	4,362
Total liabilities	78,514	49,276
Stockholders’ Equity:
Preferred Stock: $0.01 par; 3,000 shares authorized, none outstanding
Common Stock: $0.01 par; 300,000 shares authorized; 163,204 and 159,721 issued and outstanding at September 30, 2019 and December 31, 2018, respectively	1,632	1,597
Additional paid-in capital	326,895	314,907
Accumulated deficit	(283,406)	(276,800)
Accumulated other comprehensive loss	(706)	(703)
Total Stockholders' Equity	44,415	39,001
Total Liabilities and Stockholders’ Equity	$ 122,929	$ 88,277

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred Stock, par value	$ 0.01	$ 0.01
Preferred Stock, shares authorized	3,000,000	3,000,000
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.01	$ 0.01
Common Stock, shares authorized	300,000,000	300,000,000
Common Stock, shares issued	163,204,000	159,721,000
Common Stock, shares outstanding	163,204,000	159,721,000

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue:
Total revenue	$ 34,306	$ 17,868	$ 86,025	$ 44,733
Cost of revenue:
Total cost of revenue	13,062	7,289	36,449	21,435
Gross profit	21,244	10,579	49,576	23,298
Operating expenses:
Research and development	2,863	3,191	7,744	9,321
Selling, general and administrative	16,385	8,747	46,407	24,866
Total operating expenses	19,248	11,938	54,151	34,187
Operating income (loss)	1,996	(1,359)	(4,575)	(10,889)
Interest expense	(1,097)	(674)	(2,470)	(1,959)
Other income	144	97	323	199
Net income (loss)	$ 1,043	$ (1,936)	$ (6,722)	$ (12,649)
Net income (loss) per common share, basic and diluted	$ 0.01	$ (0.01)	$ (0.04)	$ (0.08)
Weighted average common shares outstanding:
Basic	163,119	157,471	162,109	157,076
Diluted	168,503	157,471	162,109	157,076
Product sales [Member]
Revenue:
Total revenue	$ 24,687	$ 11,597	$ 63,607	$ 33,641
Cost of revenue:
Total cost of revenue	12,510	6,982	33,791	20,195
Licensing and Development Revenue [Member]
Revenue:
Total revenue	1,211	2,554	4,365	5,624
Royalties [Member]
Revenue:
Total revenue	8,408	3,717	18,053	5,468
Cost of development revenue [Member]
Cost of revenue:
Total cost of revenue	$ 552	$ 307	$ 2,658	$ 1,240

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ 1,043	$ (1,936)	$ (6,722)	$ (12,649)
Foreign currency translation adjustment	(2)	(2)	(3)	(2)
Comprehensive income (loss)	$ 1,041	$ (1,938)	$ (6,725)	$ (12,651)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Loss [Member]
Balance at Dec. 31, 2017	$ 33,547	$ 1,567	$ 302,965	$ (270,285)	$ (700)
Balance, shares at Dec. 31, 2017		156,675,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(543)	$ 4	(547)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		462,000
Exercise of options	366	$ 4	362
Exercise of options, shares		384,000
Share-based compensation	3,655		3,655
Net income (loss)	(12,649)			(12,649)
Other comprehensive income (loss)	(2)				(2)
Balance at Sep. 30, 2018	24,374	$ 1,575	306,435	(282,934)	(702)
Balance, shares at Sep. 30, 2018		157,521,000
Balance at Jun. 30, 2018	24,646	$ 1,574	304,770	(280,998)	(700)
Balance, shares at Jun. 30, 2018		157,437,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(13)	$ 1	(14)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		9,000
Exercise of options	74		74
Exercise of options, shares		75,000
Share-based compensation	1,605		1,605
Net income (loss)	(1,936)			(1,936)
Other comprehensive income (loss)	(2)				(2)
Balance at Sep. 30, 2018	24,374	$ 1,575	306,435	(282,934)	(702)
Balance, shares at Sep. 30, 2018		157,521,000
Balance at Dec. 31, 2018	39,001	$ 1,597	314,907	(276,800)	(703)
Balance, shares at Dec. 31, 2018		159,721,000
Issuance of common stock,net of offering costs	7,781	$ 23	7,758
Issuance of common stock,net of offering costs, share		2,307,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(1,077)	$ 7	(1,084)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		664,000
Exercise of options	674	$ 5	669
Exercise of options, shares		512,000
Share-based compensation	4,645		4,645
Cumulative effect of change in accounting principle	116			116
Net income (loss)	(6,722)			(6,722)
Other comprehensive income (loss)	(3)				(3)
Balance at Sep. 30, 2019	44,415	$ 1,632	326,895	(283,406)	(706)
Balance, shares at Sep. 30, 2019		163,204,000
Balance at Jun. 30, 2019	41,552	$ 1,630	325,075	(284,449)	(704)
Balance, shares at Jun. 30, 2019		163,053,000
Common stock issued under equity compensation plan, net of shares withheld for taxes	(13)	$ 1	(14)
Common stock issued under equity compensation plan, net of shares withheld for taxes, shares		9,000
Exercise of options	190	$ 1	189
Exercise of options, shares		142,000
Share-based compensation	1,645		1,645
Net income (loss)	1,043			1,043
Other comprehensive income (loss)	(2)				(2)
Balance at Sep. 30, 2019	$ 44,415	$ 1,632	$ 326,895	$ (283,406)	$ (706)
Balance, shares at Sep. 30, 2019		163,204,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (6,722)	$ (12,649)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	4,645	3,655
Depreciation and amortization	1,916	1,808
Other	279	193
Changes in operating assets and liabilities:
Accounts receivable	(14,957)	(3,606)
Inventories	(5,153)	(2,000)
Contract assets	1,743	230
Prepaid expenses and other assets	847	517
Accounts payable	4,669	1,518
Accrued expenses and other liabilities	2,854	2,157
Deferred revenue	394	(1,983)
Net cash used in operating activities	(9,485)	(10,160)
Cash flows from investing activities:
Proceeds from sale of assets	2,500	7,500
Purchases of equipment, molds, furniture and fixtures	(1,274)	(526)
Additions to patent rights		(40)
Proceeds from maturities of investment securities		5,000
Net cash provided by investing activities	1,226	11,934
Cash flows from financing activities:
Proceeds from issuance of long-term debt	15,000
Payment of debt issuance costs	(136)
Proceeds from issuance of common stock, net	7,781
Proceeds from exercise of stock options	674	366
Taxes paid related to net share settlement of equity awards	(1,077)	(543)
Net cash provided by (used in) financing activities	22,242	(177)
Effect of exchange rate changes on cash	(1)	1
Net increase in cash and cash equivalents	13,982	1,598
Cash and cash equivalents:
Beginning of period	27,892	26,562
End of period	41,874	28,160
Supplemental disclosure of cash flow information:
Cash paid for interest	2,073	1,752
Supplemental disclosure of non-cash investing activities:
Purchases of equipment, molds, furniture and fixtures recorded in accounts payable and accrued expenses	$ 881	$ 56

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business	1. Description of Business Antares Pharma, Inc. (“Antares” or the “Company”) is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The Company develops and commercializes, for itself or with partners, novel therapeutic products using its advanced drug delivery technology to enhance existing drug compounds and delivery methods. The Company’s intramuscular and subcutaneous injection technology platforms include the VIBEX ® ® ® The Company markets and sells its proprietary product XYOSTED ® ® The Company also markets and sells its proprietary product OTREXUP ® Through its commercialization partner Teva, the Company sells Sumatriptan Injection USP, indicated in the U.S. for the acute treatment of migraine and cluster headache in adults. In collaboration with AMAG, the Company developed a subcutaneous auto injector for use with AMAG’s progestin hormone drug Makena ® ® Through a license, development and supply agreement with Teva, Antares developed and is the exclusive supplier of the device for Teva’s Epinephrine Injection USP, which is indicated for emergency treatment of severe allergic reactions in adults and certain pediatric patients. The product was approved by the FDA in August 2018 and launched for commercial sale in late fourth quarter of 2018. The Company is also developing two multi-dose pen injector products in collaboration with Teva, a combination drug device rescue pen in collaboration with Pfizer, and has other ongoing internal research and development programs.

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	2. Basis of Presentation and Significant Accounting Policies The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. for interim financial information and with the instructions to Form 10-Q and Article 10 of the Securities and Exchange Commission's Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The accompanying consolidated financial statements and notes thereto should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. Revisions of Prior Period Financial Statements During the preparation of the consolidated financial statements for the year ended December 31, 2018, management revised the presentation of certain regulatory fees between research and development expenses and selling, general and administrative expenses. As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows: Three months ended Nine months ended September 30, September 30, 2018 2018 Research and development, as reported $ 3,611 $ 10,581 Research and development, as revised 3,191 9,321 Selling, general and administrative, as reported 8,327 23,606 Selling, general and administrative, as revised 8,747 24,866 These revisions had no impact on the Company’s total operating expenses or net loss. The revisions also had no impact on the consolidated balance sheets or the consolidated statements of comprehensive income (loss), stockholders’ equity or cash flows. Management evaluated the materiality of the revisions from a quantitative and qualitative perspective and concluded that the revisions are immaterial to the consolidated financial statements. Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02 Leases (“Topic 842”) Recent Accounting Pronouncements Not Yet Adopted In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments In 2018, the FASB issued new guidance on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor (i.e., a service contract). Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. This standard will be effective for annual reporting periods beginning after December 15, 2019, including interim reporting periods within those fiscal years. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In 2018, the FASB issued new guidance to clarify the interaction between Collaborative Arrangements and Revenue from Contracts with Customers standards. The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for under revenue guidance, adds unit of account guidance to the collaborative arrangement guidance to align with the revenue standard, and clarifies presentation guidance for transactions with a collaborative arrangement participant that is not accounted for under the revenue standard. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim reporting periods within those annual reporting periods. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,074, and $847 at September 30, 2019 and December 31, 2018, respectively. Inventories consist of the following: September 30, December 31, 2019 2018 Inventories: Raw material $ 325 $ 26 Work in process 8,467 7,622 Finished goods 7,711 3,702 $ 16,503 $ 11,350 Equipment, Molds, Furniture, and Fixtures Equipment, molds, furniture, and fixtures are stated at cost, net of accumulated depreciation, and are depreciated using the straight-line method over their estimated useful lives ranging from three to ten years. As of September 30, 2019 and December 31, 2018, the Company’s equipment, molds, furniture and fixtures totaled $15,409 and $14,895, respectively, which is presented net of accumulated depreciation of $9,163 and $7,570 as of September 30, 2019 and December 31, 2018, respectively. Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Certain of the Company’s lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred. Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products XYOSTED ® ® The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets. Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. The Company recognized $575 in licensing and development revenue in connection with contract liabilities that were outstanding as of December 31, 2018 and satisfied during the nine months ended September 30, 2019. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of September 30, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $9.1 million. The Company expects to recognize revenue on the remaining performance obligations over the next three years.

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases	3. Leases As of January 1, 2019, the Company had operating leases for its corporate headquarters in Ewing, New Jersey and its research and development facilities in Plymouth, Minnesota. In connection with the adoption of Topic 842 on January 1, 2019, the Company recognized approximately $1.0 million in right-of-use assets and lease liabilities. During the first quarter of 2019, the Company also entered into a master operating lease arrangement for a fleet of vehicles for use by its sales force. In May 2019, the Company amended its existing lease of the Company’s corporate headquarters to extend the lease term for an additional two years. The lease extension period commences on November 1, 2019 and expires on October 31, 2021. On July 1, 2019, the Company entered into a new operating lease for approximately 75,000 square feet of office, laboratory, manufacturing and warehousing space in Minnetonka, Minnesota. The initial lease term is 12.5 years and the Company may renew the lease, at its option, for one additional renewal period of three years. The landlord delivered possession of the premises to the Company on July 1, 2019 and payment of rent will commence on January 1, 2020. The lease provides for the payment of fixed base rent and additional rent for operating expenses, insurance premiums and taxes. The Company is performing the build-out of the premises at the Company’s cost with an allowance for tenant improvement to be reimbursed by the landlord up to $1.2 million. Operating lease costs were $520 and $1,025 for the three and nine months ended September 30, 2019, respectively. Cash paid for amounts included in the measurement of operating lease liabilities was $337 and $1,053 for the three and nine months ended September 30, 2019. During the nine months ended September 30, 2019, operating lease ROU assets obtained in exchange for operating lease obligations were $5,208. As of September 30, 2019, the weighted average discount rate was approximately 9% and the weighted average remaining lease term was 7.8 years. The following table summarizes the Company’s operating lease maturities as of September 30, 2019: 2019 $ 258 2020 663 2021 1,097 2022 631 2023 638 Thereafter 5,583 Total remaining lease payments 8,870 Less: Interest (3,533 ) Total lease liabilities $ 5,337 Under the prior leasing standard, future minimum payments under non-cancellable operating leases as of December 31, 2018 were as follows: 2019 $ 566 2020 233 2021 238 2022 60 2023 — Thereafter — Total future minimum lease payments $ 1,097

Long-Term Debt

Long-Term Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Long-Term Debt	4. Long-Term Debt In June 2017, the Company entered into a loan and security agreement (the “Loan Agreement”) with Hercules Capital, Inc., for a term loan of up to $35.0 million (the “Term Loan”), under which the Company initially borrowed $25.0 million (“Tranche I”.) The amortizing Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, accrues interest at a prime-based variable rate with a maximum of 9.5%, provided for payments of interest-only until August 1, 2019 and matures on July 1, 2022. On June 26, 2019, the Company entered into a First Amendment (the “Amendment”) to the Loan Agreement, which increased the aggregate principal amount available under the Term Loan from $35.0 million to $50.0 million. Upon signing of the Amendment, an additional $15.0 million (“Tranche II”) was funded to the Company. The Company may, but is not obligated to, request one or more additional advances of at least $5.0 million, not to exceed $10.0 million in the aggregate (“Tranche III”). The Company’s option to request additional advances is available between January 1, 2020 and September 15, 2020. The Amendment extended the interest-only payment period of the Term Loan to August 1, 2021, which may be further extended to August 1, 2022 if the Company achieves a certain loan extension milestone. The Term Loan maturity date remains July 1, 2022, but may be extended to July 1, 2024 contingent upon satisfaction of a certain loan extension milestone. The Company is required to pay an end of term fee (“End of Term Charge”) equal to 4.25% of Tranche I and 3.95% of the borrowings under Tranche II and Tranche III, payable upon the earlier of July 1, 2022 or repayment of the loan. As of September 30, 2019 and December 31, 2018, the carrying value of the Term Loan was $40,269 and $25,126, respectively, which consisted of the principal amounts outstanding and the End of Term Charge accrual, less unamortized debt issuance costs that are being amortized/accrued to interest expense over the term of the Term Loan using the effective interest method. Future principal payments under the Term Loan, excluding the contractual End of Term Charges, are due in the following periods: 2019 $ — 2020 — 2021 16,179 2022 23,821 $ 40,000

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity	5. Stockholders’ Equity In August 2017, the Company entered into a sales agreement (the “Sales Agreement”) with Cowen and Company, LLC (“Cowen”) under which the Company could offer and sell, from time to time and at its sole discretion, shares of its common stock having an aggregate offering price of up to $30.0 million through Cowen as the Company’s sales agent and/or as principal. Cowen was permitted to sell the common stock through any method deemed an “at the market offering” as defined in Rule 415 of the Securities Act of 1933, as amended (the “ATM Facility”). On June 26, 2019, the Company delivered written notice to Cowen that it was terminating its Sales Agreement effective July 6, 2019, and accordingly the ATM Facility is no longer available for use. During the nine months ended September 30, 2019, the Company sold 2.3 million shares of common stock under the ATM Facility. The sale of common stock resulted in aggregate gross proceeds of $8.1 million, less sales commission and payment of offering costs, resulting in net offering proceeds to the Company of $7.8 million.

Share Based Compensation

Share Based Compensation	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation	6 . Share-Based Compensation The Company has an Equity Compensation Plan (the “Plan”), which was amended and restated pursuant to stockholder approval on June 13, 2019 in order to increase the number of shares available for issuance under the Plan, extend the term of the Plan and modify certain provisions. The Plan allows for grants in the form of incentive stock options, nonqualified stock options, stock units, stock awards, stock appreciation rights, and other stock-based awards. All of the Company’s officers, directors, employees, consultants and advisors are eligible to receive grants under the Plan. The maximum number of shares authorized for issuance under the Plan is 40.2 million and the maximum number of shares of stock that may be granted to any one employee for qualified performance-based compensation during a calendar year is four million shares. Options to purchase shares of common stock are granted at exercise prices not less than 100% of fair market value on the dates of grant. The term of each option is ten years and the options typically vest over a three-year period with a minimum vesting period of one year. As of September 30, 2019, the Plan had approximately 7.5 million shares available for grant. Stock option exercises are satisfied through the issuance of new shares. The Company’s Board of Directors (the “Board”) has also approved a long-term incentive program (“LTIP”), pursuant to which the Company’s senior executives have been awarded stock options, restricted stock units (“RSUs”) and performance stock units (“PSUs”) with targeted values based on values granted to similarly situated senior executives in the Company’s peer group. The stock options have a ten-year term, have an exercise price equal to the closing price of the Company’s common stock on the date of grant, vest in annual installments over three years, and are granted on the same standard terms and conditions as other stock options granted pursuant to the Plan. The RSU awards made to senior executives vest and convert into shares of the Company’s stock in three equal annual installments. The PSU awards vest and convert into shares of the Company’s common stock based on the Company’s attainment of certain performance goals as established by the Board over a performance period, which is typically three years. A portion of the compensation provided to non-employee members of the Board is awarded in the form of stock options and RSUs, which vest in full one year from the date of grant and are otherwise granted on the same standard terms and conditions as other awards granted under the Plan. The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2019: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2018 14,079 $ 2.19 Granted 2,380 2.93 Exercised (512 ) 1.32 Cancelled/Forfeited (110 ) 2.16 Outstanding at September 30, 2019 15,837 2.33 6.5 $ 16,472 Exercisable at September 30, 2019 11,736 $ 2.15 5.5 $ 14,368 The weighted average grant date fair value per share for options granted during the nine months ended September 30, 2019 and 2018 was $1.50 and $1.44, respectively, which was estimated using the Black-Scholes option pricing model based on the assumptions noted in the table below. Expected volatilities are based on the historical volatility of the Company’s stock price. The weighted average expected life is based on both historical and anticipated employee behavior. September 30, 2019 2018 Risk-free interest rate 1.9% 2.8% Annualized volatility 55.8% 53.7% Weighted average expected life, in years 5.5 6.0 Expected dividend yield 0.0% 0.0% The following is a summary of PSU and RSU award activity under the Plan as of and for the nine months ended September 30, 2019: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2018 1,842 $ 2.41 1,226 $ 2.44 Granted 593 2.99 789 2.92 Vested/settled (415 ) 1.18 (614 ) 2.19 Forfeited/expired (178 ) 1.12 — — Outstanding at September 30, 2019 1,842 $ 3.01 1,401 $ 2.82 The PSUs granted to senior executives under the LTIP may be earned based upon the Company’s achievement of certain corporate development goals, net revenue goals and total shareholder return (“TSR”) relative to the Nasdaq Biotechnology Index over the performance period, which is generally a three-year period. Depending on the outcome of the performance goals, a recipient may ultimately earn a number of shares greater or less than the target number of shares granted, ranging from 0% to 150%. The fair value of the TSR PSUs are expensed over the performance period and determined using a Monte Carlo simulation. The grant date fair value of PSUs that are not tied to market-based performance are expensed over the remaining performance period when it becomes probable that the related goal will be achieved. The LTIP awards that vested during the nine months ended September 30, 2019 and 2018 were net-share settled such that the Company withheld shares with a value equivalent to the employees’ tax obligations for applicable income and other employment taxes, and remitted cash to the appropriate taxing authorities. The Company withheld 365 and 211 shares during the nine months ended September 30, 2019 and 2018, respectively, to satisfy tax obligations, which was determined based on the fair value of the shares on their vesting date equal to the Company’s closing stock price on such date. The Company paid $1,077 and $543 during the nine months ended September 30, 2019 and 2018, respectively, to taxing authorities for the employees’ tax obligations, which is reflected as a cash outflow from financing activities within the consolidated statements of cash flows. Net-share settlements have the effect of share repurchases by the Company as they reduce the number of shares that would have otherwise been issued as a result of the vesting. In connection with Plan awards, the Company recognized share-based compensation expense for the three and nine months ended September 30, 2019 and 2018 as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Stock options $ 888 $ 811 $ 2,555 $ 2,158 Restricted stock units 565 338 1,267 861 Performance stock units 192 456 823 636 Total share-based compensation expense $ 1,645 $ 1,605 $ 4,645 $ 3,655

Revenues, Significant Customers

Revenues, Significant Customers and Concentrations of Risk	9 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Revenues, Significant Customers and Concentrations of Risk	7 . Revenues, Significant Customers and Concentrations of Risk The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines: Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 Proprietary product sales $ 11,458 $ 4,094 $ 25,213 $ 11,820 Partnered product sales 13,229 7,503 38,394 21,821 Total product revenue 24,687 11,597 63,607 33,641 Licensing and development revenue 1,211 2,554 4,365 5,624 Royalties 8,408 3,717 18,053 5,468 Total revenue $ 34,306 $ 17,868 $ 86,025 $ 44,733 Revenues disaggregated by customer location are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 United States of America $ 33,684 $ 16,027 $ 82,411 $ 39,448 Europe 566 1,830 3,444 5,044 Other 56 11 170 241 $ 34,306 $ 17,868 $ 86,025 $ 44,733 The following table identifies customers from which the Company derived 10% or more of its total revenue in any of the periods presented: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Teva 41% 34% 43% 33% AMAG 20% 30% 19% 27% McKesson <10% <10% <10% 11% AmerisourceBergen 10% 11% <10% 11% Ferring <10% 12% <10% 13%

Sale of Assets

Sale of Assets	9 Months Ended
	Sep. 30, 2019
Sale Of Assets [Abstract]
Sale of Assets	8. Sale of Assets In October 2017, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Ferring International Center S.A. (together with Ferring Pharmaceuticals Inc. and Ferring B.V. individually and collectively referred to as “Ferring”) to sell the worldwide rights, including certain assets, related to the needle-free auto injector device product line for a total purchase price of $14.5 million. The purchase price was to be paid in four installments consisting of the following: a $2.0 million upfront payment, which was received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million received upon delivery of certain documentation and satisfaction of certain conditions primarily related to product manufacturing; a third installment of $4.75 million received upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million due upon Ferring’s receipt of the CE Mark needed to continue to commercialize the product in certain territories and the final transfer of certain product-related inventory, equipment and agreements to Ferring (the “Completion Date”). On May 1, 2019, the Company and Ferring entered into the First Amendment of the Asset Purchase Agreement (the “First Amendment”) to extend the term of the agreement to the third anniversary, to provide for the manufacture and delivery of additional product by Antares to Ferring prior to the Completion Date, and to bifurcate the payment of the final installment of the purchase price such that $2.5 million was paid to the Company upon the First Amendment effective date, with the final remaining payment of $2.5 million to be paid at the Completion Date, which was received in October 2019. The Company previously recorded the gain on sale of assets as it was determined that, based on the satisfaction of certain conditions and the status of remaining closing requirements, it was probable that a significant reversal of the gain will not occur. The receipt of the $2.5 million in the nine months ended September 30, 2019 was recorded as a reduction in the related contract asset balance and a cash inflow from investing activities in the consolidated statement of cash flows.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Earnings Per Share	9 . Earnings Per Share Basic earnings or loss per common share is computed by dividing the net income or loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share is computed in a similar manner, except that the weighted average number of shares outstanding is increased to reflect the potential dilution from the exercise or conversion of securities into common stock. Diluted earnings per share contemplate a complete conversion to common shares of all convertible instruments only if such instruments are dilutive in nature with respect to earnings per share. The dilutive effect of stock options and other equity-based awards included in the diluted weighted average common shares outstanding used in the computation of diluted earnings per share for the three months ended September 30, 2019 was 5,385. The potentially dilutive stock options and other share-based awards excluded from the calculation of loss per share for the nine months ended September 30, 2019 and the three and nine months ended September 30, 2018 because their effect was anti-dilutive totaled 19,080 and 17,386 at September 30, 2019 and 2018, respectively.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies Pending Litigation From time to time, the Company may be involved in various legal matters generally incidental to its business. Although the results of litigation and claims cannot be predicted with certainty, after discussion with legal counsel, management is not aware of any matters for which the likelihood of a loss is probable and reasonably estimable and which could have a material impact on its consolidated financial condition, liquidity, or results of operations. On October 23, 2017, Randy Smith filed a complaint in the District of New Jersey, captioned Randy Smith, Individually and on Behalf of All Others Similarly Situated v. Antares Pharma, Inc., Robert F. Apple and Fred M. Powell Smith ® ® Smith On January 12, 2018, a stockholder of the Company filed a derivative civil action, captioned Chiru Mackert, derivatively on behalf of Antares Pharma, Inc., v. Robert F. Apple, et al. Vikram Rao, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Smith Smith On January 17, 2018, a stockholder of the Company filed a derivative civil action, captioned Robert Clark, Derivatively on Behalf of Antares Pharma, Inc. v. Robert F. Apple, et al. Clark Smith Clark Smith

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Revisions of Prior Period Financial Statements	Revisions of Prior Period Financial Statements During the preparation of the consolidated financial statements for the year ended December 31, 2018, management revised the presentation of certain regulatory fees between research and development expenses and selling, general and administrative expenses. As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows: Three months ended Nine months ended September 30, September 30, 2018 2018 Research and development, as reported $ 3,611 $ 10,581 Research and development, as revised 3,191 9,321 Selling, general and administrative, as reported 8,327 23,606 Selling, general and administrative, as revised 8,747 24,866 These revisions had no impact on the Company’s total operating expenses or net loss. The revisions also had no impact on the consolidated balance sheets or the consolidated statements of comprehensive income (loss), stockholders’ equity or cash flows. Management evaluated the materiality of the revisions from a quantitative and qualitative perspective and concluded that the revisions are immaterial to the consolidated financial statements.
Recent Accounting Pronouncements	Accounting Pronouncements Recently Adopted The Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2016-02 Leases (“Topic 842”) Recent Accounting Pronouncements Not Yet Adopted In 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments In 2018, the FASB issued new guidance on a customer's accounting for implementation, set-up, and other upfront costs incurred in a cloud computing arrangement that is hosted by the vendor (i.e., a service contract). Under the new guidance, customers will apply the same criteria for capitalizing implementation costs as they would for an arrangement that has a software license. This standard will be effective for annual reporting periods beginning after December 15, 2019, including interim reporting periods within those fiscal years. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements. In 2018, the FASB issued new guidance to clarify the interaction between Collaborative Arrangements and Revenue from Contracts with Customers standards. The guidance clarifies that certain transactions between collaborative arrangement participants should be accounted for under revenue guidance, adds unit of account guidance to the collaborative arrangement guidance to align with the revenue standard, and clarifies presentation guidance for transactions with a collaborative arrangement participant that is not accounted for under the revenue standard. The guidance is effective for annual reporting periods beginning after December 15, 2019, including interim reporting periods within those annual reporting periods. The Company does not expect the adoption of this standard to have a material impact on its consolidated financial statements.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first-in, first-out basis. Certain components of the Company’s products are provided by a limited number of vendors, and the Company’s production, assembly, warehousing and distribution operations are outsourced to third-parties where substantially all of the Company’s inventory is located. Disruption of supply from key vendors or third-party suppliers may have a material adverse impact on the Company’s operations. The Company provides a reserve for potentially excess, dated or obsolete inventories based on an analysis of inventory on hand compared to forecasts of future sales, which was $1,074, and $847 at September 30, 2019 and December 31, 2018, respectively. Inventories consist of the following: September 30, December 31, 2019 2018 Inventories: Raw material $ 325 $ 26 Work in process 8,467 7,622 Finished goods 7,711 3,702 $ 16,503 $ 11,350
Equipment, Molds, Furniture, and Fixtures	Equipment, Molds, Furniture, and Fixtures
Leases	Leases The Company recognizes right-of-use (“ROU”) assets and lease liabilities when it obtains the right to control an asset under a leasing arrangement with an initial term greater than twelve months. The Company evaluates the nature of each lease at the inception of an arrangement to determine whether it is an operating or financing lease and recognizes the right-of-use asset and lease liabilities based on the present value of future minimum lease payments over the expected lease term. The Company’s leases do not generally contain an implicit interest rate and therefore the Company uses the incremental borrowing rate it would expect to pay to borrow on a similar collateralized basis over a similar term in order to determine the present value of its lease payments. Certain of the Company’s lease arrangements contain renewal options that have not been included in the determination of the lease term, as they are not reasonably certain of exercise. For contracts that contain lease and non-lease components, the Company accounts for both components as a single lease component. Variable lease payments are expensed as incurred.
Revenue Recognition	Revenue Recognition The Company generates revenue from proprietary and partnered product sales, license and development activities and royalty arrangements. Revenue is recognized when or as the Company transfers control of the promised goods or services to its customers at the transaction price, which is the amount that reflects the consideration to which it expects to be entitled to in exchange for those goods or services. At inception of each contract, the Company identifies the goods and services that have been promised to the customer and each of those that represent a distinct performance obligation, determines the transaction price including any variable consideration, allocates the transaction price to the distinct performance obligations and determines whether control transfers to the customer at a point in time or over time. Variable consideration is included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. The Company reassesses its reserves for variable consideration at each reporting date and makes adjustments, if necessary, The Company has elected to recognize the cost for freight and shipping activities as fulfilment cost. Amounts billed to customers for shipping and handling are included as part of the transaction price and recognized as revenue when control of underlying goods are transferred to the customer. The related shipping and freight charges incurred by the Company are included in cost of revenue. Proprietary Product Sales The Company sells its proprietary products XYOSTED ® ® The determination of certain of these reserves and sales allowances require management to make a number of judgements and estimates to reflect the Company’s best estimate of the transaction price and the amount of consideration to which it believes it is ultimately entitled to receive. The expected value is determined based on unit sales data, contractual terms with customers and third-party payers, historical and expected utilization rates, any new or anticipated changes in programs or regulations that would impact the amount of the actual rebates, customer purchasing patterns, product expiration dates and levels of inventory in the distribution channel. Reserves for prompt payment discounts are recorded as a reduction in accounts receivable. Reserves for returns, rebates and chargebacks, distributor fees and customer co-pay support programs are included within current liabilities in the consolidated balance sheets. Partnered Product Sales The Company is party to several license, development, supply and distribution arrangements with pharmaceutical partners, under which the Company produces and is the exclusive supplier of certain products, devices and/or components. Revenue is recognized when or as control of the goods transfers to the customer as follows: The Company is the exclusive supplier of the Makena ® All other partnered product sales are recognized at the point in time in which control is transferred to the customer, which is typically upon shipment. Sales terms and pricing are governed by the respective supply and distribution agreements, and there is generally no price protection or right of return. Revenue is recognized at the transaction price, which includes the contractual per unit selling price and estimated variable consideration, if any. For example, the Company sells Sumatriptan Injection USP to Teva at cost and is entitled to receive 50 percent of the net profits from commercial sales made by Teva, payable to the Company within 45 days after the end of the quarter in which the commercial sales are made. The Company recognizes revenue, including the estimated variable consideration it expects to receive for contract margin on future commercial sales, upon shipment of the goods to Teva. The estimated variable consideration is recognized at an amount the Company believes is not subject to significant reversal based on historical experience, and is adjusted at each reporting period if the most likely amount of expected consideration changes or becomes fixed. Licensing and Development Revenue The Company has entered into several license, development and supply arrangements with pharmaceutical partners under which the Company grants a license to its device technology and know-how and provides research and development services that often involve multiple performance obligations and highly customized deliverables. For such arrangements, the Company identifies each of the promised goods and services within the contract and the distinct performance obligations at inception, and allocates consideration to each performance obligation based on relative standalone selling price, which is generally determined based on the expected cost plus margin. If the contract includes an enforceable right to payment for performance completed to date and performance obligations are satisfied over time, the Company recognized revenue over the development period using either the input or output method depending on which is most appropriate given the nature of the distinct deliverable. For other contracts that do not contain an enforceable right to payment for performance completed to date, revenue is recognized when control is transferred to the customer. Factors that may indicate that the transfer of control has occurred include the transfer of legal title, transfer of physical possession, the customer has obtained the significant risks and rewards of ownership of the assets and the Company has a present right to payment. The Company’s typical payment terms for development contracts may include an upfront payment equal to a percentage of the total contract value with the remaining portion to be billed upon completion and transfer of the individual deliverables or satisfaction of the individual performance obligations. The Company records a liability for cash received in advance of performance, which is presented within deferred revenue on the consolidated balance sheet and recognized as revenue when the associated performance obligations have been satisfied. The Company recognized $575 in licensing and development revenue in connection with contract liabilities that were outstanding as of December 31, 2018 and satisfied during the nine months ended September 30, 2019. License fees and milestones received in exchange for the grant of a license to the Company’s functional intellectual property such as patented technology and know-how in connection with a partnered development arrangement are generally recognized at inception of the arrangement, or over the development period depending on the facts and circumstances, as the license is not generally distinct from the non-licensed goods or services to be provided under the contract. Milestone payments that are contingent upon the occurrence of future events, are evaluated and recorded at the most likely amount, and to the extent that it is probable that a significant reversal will not occur when the associated uncertainty is resolved. Royalties The Company earns royalties in connection with licenses granted under license and development arrangements with partners. Royalties are based upon a percentage of commercial sales of partnered products with rates ranging from mid-single digit to low double digit and are tiered based on levels of net sales. These sales-based royalties, for which the license was deemed the predominant element to which the royalties relate, are estimated and recognized in the period in which the partners’ commercial sales occur. The royalties are generally reported and payable to the Company within 45 to 60 days of the end of the period in which the commercial sales are made. The Company bases its estimates of royalties earned on actual sales information from its partners when available or estimated prescription sales from external sources and estimated net selling price. If actual royalties received are different than amounts estimated, the Company would adjust the royalty revenue in the period in which the adjustment becomes known. Remaining Performance Obligations Remaining performance obligations represents the allocation of transaction price of firm orders and development contract deliverables for which work has not been completed or orders fulfilled, and excludes potential purchase orders under ordering-type supply contracts with indefinite delivery or quantity. As of September 30, 2019, the aggregate value of remaining performance obligations, excluding contracts with an original expected length of one year or less, was $9.1 million. The Company expects to recognize revenue on the remaining performance obligations over the next three years.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Revisions to Prior Period Interim Consolidated Statements of Operations	As a result, the Company also made revisions to its prior period interim consolidated statements of operations as follows: Three months ended Nine months ended September 30, September 30, 2018 2018 Research and development, as reported $ 3,611 $ 10,581 Research and development, as revised 3,191 9,321 Selling, general and administrative, as reported 8,327 23,606 Selling, general and administrative, as revised 8,747 24,866
Inventories	Inventories consist of the following: September 30, December 31, 2019 2018 Inventories: Raw material $ 325 $ 26 Work in process 8,467 7,622 Finished goods 7,711 3,702 $ 16,503 $ 11,350

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Summary of Operating Lease Maturities	The following table summarizes the Company’s operating lease maturities as of September 30, 2019: 2019 $ 258 2020 663 2021 1,097 2022 631 2023 638 Thereafter 5,583 Total remaining lease payments 8,870 Less: Interest (3,533 ) Total lease liabilities $ 5,337
Summary of Future Minimum Lease Payments Under Non - Cancellable Operating Leases	Under the prior leasing standard, future minimum payments under non-cancellable operating leases as of December 31, 2018 were as follows: 2019 $ 566 2020 233 2021 238 2022 60 2023 — Thereafter — Total future minimum lease payments $ 1,097

Long-Term Debt (Tables)

Long-Term Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Future Principal Payments under Term Loan, Excluding End of Term Charges	Future principal payments under the Term Loan, excluding the contractual End of Term Charges, are due in the following periods: 2019 $ — 2020 — 2021 16,179 2022 23,821 $ 40,000

Share Based Compensation (Table

Share Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	The following is a summary of stock option activity under the Plan as of and for the nine months ended September 30, 2019: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Shares Price Term (Years) Value Outstanding at December 31, 2018 14,079 $ 2.19 Granted 2,380 2.93 Exercised (512 ) 1.32 Cancelled/Forfeited (110 ) 2.16 Outstanding at September 30, 2019 15,837 2.33 6.5 $ 16,472 Exercisable at September 30, 2019 11,736 $ 2.15 5.5 $ 14,368
Assumptions Used in Fair Value Measurement of Options Granted	September 30, 2019 2018 Risk-free interest rate 1.9% 2.8% Annualized volatility 55.8% 53.7% Weighted average expected life, in years 5.5 6.0 Expected dividend yield 0.0% 0.0%
Summary of PSU and RSU Award Activity Under Plan	The following is a summary of PSU and RSU award activity under the Plan as of and for the nine months ended September 30, 2019: Performance Stock Units Restricted Stock Units Number of Shares Weighted Average Date Fair Value Number of Shares Weighted Average Grant Date Fair Value Outstanding at December 31, 2018 1,842 $ 2.41 1,226 $ 2.44 Granted 593 2.99 789 2.92 Vested/settled (415 ) 1.18 (614 ) 2.19 Forfeited/expired (178 ) 1.12 — — Outstanding at September 30, 2019 1,842 $ 3.01 1,401 $ 2.82
Summary of Share Based Compensation Allocation Expense	In connection with Plan awards, the Company recognized share-based compensation expense for the three and nine months ended September 30, 2019 and 2018 as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Stock options $ 888 $ 811 $ 2,555 $ 2,158 Restricted stock units 565 338 1,267 861 Performance stock units 192 456 823 636 Total share-based compensation expense $ 1,645 $ 1,605 $ 4,645 $ 3,655

Revenues, Significant Custome_2

Revenues, Significant Customers and Concentrations of Risk (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue From Contract With Customer [Abstract]
Summary of Revenues Disaggregated by Types of Goods and Services and Major Product and Customer Location	The following table presents the Company’s revenue on a disaggregated basis by types of goods and services and major product lines: Three months ended September 30, Nine months ended September 30, 2019 2018 2019 2018 Proprietary product sales $ 11,458 $ 4,094 $ 25,213 $ 11,820 Partnered product sales 13,229 7,503 38,394 21,821 Total product revenue 24,687 11,597 63,607 33,641 Licensing and development revenue 1,211 2,554 4,365 5,624 Royalties 8,408 3,717 18,053 5,468 Total revenue $ 34,306 $ 17,868 $ 86,025 $ 44,733 Revenues disaggregated by customer location are as follows: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 United States of America $ 33,684 $ 16,027 $ 82,411 $ 39,448 Europe 566 1,830 3,444 5,044 Other 56 11 170 241 $ 34,306 $ 17,868 $ 86,025 $ 44,733
Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue	The following table identifies customers from which the Company derived 10% or more of its total revenue in any of the periods presented: Three Months Ended Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Teva 41% 34% 43% 33% AMAG 20% 30% 19% 27% McKesson <10% <10% <10% 11% AmerisourceBergen 10% 11% <10% 11% Ferring <10% 12% <10% 13%

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies - Summary of Revisions to Prior Period Interim Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development	$ 2,863	$ 3,191	$ 7,744	$ 9,321
Selling, general and administrative	$ 16,385	8,747	$ 46,407	24,866
As Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Research and development		3,611		10,581
Selling, general and administrative		$ 8,327		$ 23,606

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
Summary of Significant Accounting Policies [Line Items]
Right-of-use assets	$ 5,462
Lease liability	5,337
Inventory reserve	1,074		$ 847
Equipment, molds, furniture and fixtures, net	15,409		14,895
Accumulated depreciation	9,163		$ 7,570
Remaining performance obligations	$ 9,100
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Explanation	The Company expects to recognize revenue on the remaining performance obligations over the next three years.
Licensing and Development Revenue [Member]
Summary of Significant Accounting Policies [Line Items]
Revenue recognized	$ 575
Teva [Member]
Summary of Significant Accounting Policies [Line Items]
Future net profits from commercial sales percent	50.00%
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	3 years
Royalty payment period	45 days
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Estimated useful lives	10 years
Royalty payment period	60 days
ASU 2016-02 [Member]
Summary of Significant Accounting Policies [Line Items]
Right-of-use assets		$ 1,000
Lease liability		$ 1,000

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies - Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw material	$ 325	$ 26
Work in process	8,467	7,622
Finished goods	7,711	3,702
Inventory, Total	$ 16,503	$ 11,350

Leases - Additional Information

Leases - Additional Information (Detail)	Jul. 01, 2019USD ($)ft²	Sep. 30, 2019USD ($)	Sep. 30, 2019USD ($)	Jan. 01, 2019USD ($)
Regulatory Assets [Line Items]
Right-of-use assets		$ 5,462,000	$ 5,462,000
Lease liability		$ 5,337,000	$ 5,337,000
Lessee, operating lease, extension term	3 years	2 years	2 years
Lessee, operating lease, existence of option to extend			true
Description of operating lease extension period			In May 2019, the Company amended its existing lease of the Company’s corporate headquarters to extend the lease term for an additional two years. The lease extension period commences on November 1, 2019 and expires on October 31, 2021
Leased area | ft²	75,000
Lease term	12 years 6 months
Lease renewal term	3 years	2 years	2 years
Operating lease costs		$ 520,000	$ 1,025,000
Cash paid for operating lease liabilities		$ 337,000	1,053,000
Operating lease ROU assets obtained in exchange for operating lease obligations			$ 5,208,000
Weighted average discount rate		9.00%	9.00%
Weighted average remaining lease term		7 years 9 months 18 days	7 years 9 months 18 days
Maximum [Member]
Regulatory Assets [Line Items]
Operating lease, allowance	$ 1,200,000
ASU 2016-02 [Member]
Regulatory Assets [Line Items]
Right-of-use assets				$ 1,000,000
Lease liability				$ 1,000,000

Leases - Summary of Operating L

Leases - Summary of Operating Lease Maturities (Detail) $ in Thousands	Sep. 30, 2019USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2019	$ 258
2020	663
2021	1,097
2022	631
2023	638
Thereafter	5,583
Total remaining lease payments	8,870
Less: Interest	(3,533)
Total lease liabilities	$ 5,337

Leases - Summary of Future Mini

Leases - Summary of Future Minimum Lease Payments Under Non - Cancellable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2019	$ 566
2020	233
2021	238
2022	60
Total future minimum lease payments	$ 1,097

Long-Term Debt - Additional Inf

Long-Term Debt - Additional Information (Detail) - USD ($)	Jun. 26, 2019	Jun. 30, 2017	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Proceeds from issuance of long-term debt			$ 15,000,000
Carrying value of long term debt			$ 40,269,000	$ 22,083,000
Hercules Capital, Inc [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Long-tem debt, face amount	$ 50,000,000
Debt instrument, maturity date Description			The amortizing Term Loan is secured by substantially all of the Company’s assets, excluding intellectual property, accrues interest at a prime-based variable rate with a maximum of 9.5%, provided for payments of interest-only until August 1, 2019 and matures on July 1, 2022.
Debt instrument, maturity date			Jul. 1, 2022
Debt instrument, payment terms			The Amendment extended the interest-only payment period of the Term Loan to August 1, 2021, which may be further extended to August 1, 2022 if the Company achieves a certain loan extension milestone.
Carrying value of long term debt			$ 40,269,000	$ 25,126,000
Hercules Capital, Inc [Member] | Term Loan [Member] | Maximum [Member]
Debt Instrument [Line Items]
Long-tem debt, face amount		$ 35,000,000
Hercules Capital, Inc [Member] | Term Loan [Member] | Tranche I [Member]
Debt Instrument [Line Items]
Proceeds from issuance of long-term debt		$ 25,000,000
Hercules Capital, Inc [Member] | Term Loan [Member] | Prime Based Variable Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, variable interest rate			9.50%
Hercules Capital, Inc [Member] | Tranche II [Member]
Debt Instrument [Line Items]
Long-term debt, increase in face amount	15,000,000
Percentage of loan fee on original principal amount			3.95%
Hercules Capital, Inc [Member] | Tranche III [Member]
Debt Instrument [Line Items]
Percentage of loan fee on original principal amount			3.95%
Hercules Capital, Inc [Member] | Tranche III [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, available option to request addditional advance amount	10,000,000
Hercules Capital, Inc [Member] | Tranche III [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, available option to request addditional advance amount	$ 5,000,000
Hercules Capital, Inc [Member] | Tranche I Loan [Member]
Debt Instrument [Line Items]
Percentage of loan fee on original principal amount			4.25%

Long-Term Debt - Schedule of Fu

Long-Term Debt - Schedule of Future Principal Payments under Term Loan, Excluding End of Term Charges (Detail) $ in Thousands	Sep. 30, 2019USD ($)
Debt Disclosure [Abstract]
2021	$ 16,179
2022	23,821
Long-term debt	$ 40,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 31, 2017	Sep. 30, 2019
Stockholders Equity [Line Items]
Aggregate offering price of common stock		$ 7,781,000
Proceeds from sale of common stock		$ 7,781,000
Sales Agreement [Member] | Cowen and Company, LLC [Member] | Maximum [Member]
Stockholders Equity [Line Items]
Aggregate offering price of common stock	$ 30,000,000
ATM Facility [Member]
Stockholders Equity [Line Items]
Issuance of common stock, shares		2,300,000
Gross proceeds from sale of common stock		$ 8,100,000
Proceeds from sale of common stock		$ 7,800,000

Share Based Compensation - Addi

Share Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares withheld to meet employees' statutory income tax obligation	365,000	211,000
Amounts paid to taxing authorities for employees’ tax obligations	$ 1,077	$ 543
Employees Tax Obligations [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Amounts paid to taxing authorities for employees’ tax obligations	$ 1,077	$ 543
Amended and Restated Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized	40,200,000
Maximum number of shares of stock granted to one participant	4,000,000
Minimum percentage of exercise price	100.00%
Shares available for grant under the plan	7,500
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value per share for options granted	$ 1.50	$ 1.44
Stock Options [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted	10 years
Vesting period	3 years
Stock Options [Member] | Amended and Restated Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term of options granted	10 years
Vesting period	3 years
Stock Options [Member] | Minimum [Member] | Amended and Restated Equity Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Restricted Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Stock Units [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Performance Stock Units [Member] | Minimum [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage	0.00%
Performance Stock Units [Member] | Maximum [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation award percentage	150.00%
Stock Options and RSUs [Member] | Long Term Incentive Program [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

Share Based Compensation - Summ

Share Based Compensation - Summary of Stock Option Activity (Detail) $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Stockholders Equity Note [Abstract]
Number of Shares Outstanding, Beginning Balance | shares	14,079,000
Number of Shares Granted | shares	2,380,000
Number of Shares Exercised | shares	(512,000)
Number of Shares Cancelled/Forfeited | shares	(110,000)
Number of Shares Outstanding, Ending Balance | shares	15,837,000
Number of Shares Exercisable, Ending Balance | shares	11,736,000
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 2.19
Weighted Average Exercise Price Granted | $ / shares	2.93
Weighted Average Exercise Price Exercised | $ / shares	1.32
Weighted Average Exercise Price Cancelled/Forfeited | $ / shares	2.16
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	2.33
Weighted Average Exercise Price Exercisable, Ending Balance | $ / shares	$ 2.15
Weighted Average Remaining Contractual Term (Years) Outstanding, Ending Balance	6 years 6 months
Weighted Average Remaining Contractual Term (Years) Exercisable, Ending Balance	5 years 6 months
Aggregate Intrinsic Value Outstanding, Ending Balance | $	$ 16,472
Aggregate Intrinsic Value Exercisable, Ending Balance | $	$ 14,368

Share Based Compensation - Assu

Share Based Compensation - Assumptions Used in Fair Value Measurement of Options Granted (Detail)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Stockholders Equity Note [Abstract]
Risk-free interest rate	1.90%	2.80%
Annualized volatility	55.80%	53.70%
Weighted average expected life, in years	5 years 6 months	6 years
Expected dividend yield	0.00%	0.00%

Share Based Compensation - Su_2

Share Based Compensation - Summary of PSU and RSU Award Activity Under Plan (Detail)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	1,842,000
Number of Shares, Granted | shares	593,000
Number of Shares, Vested/settled | shares	(415,000)
Number of Shares, Forfeited/expired | shares	(178,000)
Number of Shares, Ending Balance | shares	1,842,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.41
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.99
Weighted Average Grant Date Fair Value, Vested/settled | $ / shares	1.18
Weighted Average Grant Date Fair Value, Forfeited/expired | $ / shares	1.12
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 3.01
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Beginning Balance | shares	1,226,000
Number of Shares, Granted | shares	789,000
Number of Shares, Vested/settled | shares	(614,000)
Number of Shares, Ending Balance | shares	1,401,000
Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares	$ 2.44
Weighted Average Grant Date Fair Value, Granted | $ / shares	2.92
Weighted Average Grant Date Fair Value, Vested/settled | $ / shares	2.19
Weighted Average Grant Date Fair Value, Ending Balance | $ / shares	$ 2.82

Share Based Compensation - Su_3

Share Based Compensation - Summary of Share Based Compensation Allocation Expense (Detail) - Long Term Incentive Program [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 1,645	$ 1,605	$ 4,645	$ 3,655
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	888	811	2,555	2,158
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	565	338	1,267	861
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 192	$ 456	$ 823	$ 636

Revenues, Significant Custome_3

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenue Disaggregated by Types of Goods and Services and Major Product (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 34,306	$ 17,868	$ 86,025	$ 44,733
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	24,687	11,597	63,607	33,641
Total Product Revenue [Member] | Proprietary Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	11,458	4,094	25,213	11,820
Total Product Revenue [Member] | Partnered Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	13,229	7,503	38,394	21,821
Licensing and Development Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,211	2,554	4,365	5,624
Royalties [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 8,408	$ 3,717	$ 18,053	$ 5,468

Revenues, Significant Custome_4

Revenues, Significant Customers and Concentrations of Risk - Summary of Revenues Disaggregated by Customer Location (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenues	$ 34,306	$ 17,868	$ 86,025	$ 44,733
United States of America [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	33,684	16,027	82,411	39,448
Europe [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	566	1,830	3,444	5,044
Other [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	$ 56	$ 11	$ 170	$ 241

Revenues, Significant Custome_5

Revenues, Significant Customers and Concentrations of Risk - Summary of Significant Customers from which the Company Derived 10% or More of Total Revenue (Detail) - Customer Concentration Risk [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Teva [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	41.00%	34.00%	43.00%	33.00%
AMAG [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	20.00%	30.00%	19.00%	27.00%
McKesson [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage				11.00%
McKesson [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	10.00%	10.00%	10.00%
AmerisourceBergen [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	10.00%	11.00%		11.00%
AmerisourceBergen [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage			10.00%
Ferring [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage		12.00%		13.00%
Ferring [Member] | Maximum [Member]
Concentration Risk [Line Items]
Total revenue by customer, percentage	10.00%		10.00%

Sale of Assets - Additional Inf

Sale of Assets - Additional Information (Detail) $ in Thousands	May 01, 2019USD ($)	Oct. 31, 2019USD ($)	Oct. 31, 2017USD ($)Installment	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)
Sale Of Assets [Line Items]
Gain on sale of assets				$ 2,500	$ 7,500
Asset Purchase Agreement [Member] | Ferring [Member]
Sale Of Assets [Line Items]
Total purchase price			$ 14,500
Number of installments paid for purchase price | Installment			4
Description of purchase price payment				The purchase price was to be paid in four installments consisting of the following: a $2.0 million upfront payment, which was received upon entry into the Asset Purchase Agreement and the transfer of certain assets; a second installment of $2.75 million received upon delivery of certain documentation and satisfaction of certain conditions primarily related to product manufacturing; a third installment of $4.75 million received upon satisfaction of certain conditions, including further document transfer, the successful completion of a regulatory audit by a notified body, and a pilot manufacturing run under Ferring’s supervision; and a final installment of $5.0 million due upon Ferring’s receipt of the CE Mark needed to continue to commercialize the product in certain territories and the final transfer of certain product-related inventory, equipment and agreements to Ferring (the “Completion Date”).
Upfront payment received upon transfer of assets			$ 2,000
Consideration receivable on criteria completion related to product manufacturing			2,750
Consideration receivable on criteria completion related to Audit and pilot manufacturing			4,750
Consideration receivable on criteria completion related to Product commercialization			$ 5,000
Payment of final installment purchase price	$ 2,500
Gain on sale of assets				$ 2,500
Asset Purchase Agreement [Member] | Ferring [Member] | Subsequent Event [Member]
Sale Of Assets [Line Items]
Final remaining payment received in completion date		$ 2,500

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Potentially dilutive stock options and other share-based awards excluded from dilutive loss per share		19,080,000	17,386,000
Dilutive effect of stock options and other equity-based awards	5,385,000